Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Cambridge, UK and Indianapolis, US – 13 October 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that on 12 October 2020, the Company's Employee Benefit Trust ("EBT") transferred 75,000 ordinary shares of 0.2 pence in the Company (the "Ordinary Shares") to Michael Bolinder following the vesting of share awards granted under the Company's Performance Share Plan.

Following the transfer of the Ordinary Shares referred to above. Michael Bolinder holds 75,000 Ordinary Shares, representing 0.08 per cent. of the total issued share capital of the Company.

1Details of the person discharging managerial responsibilities/person closely associated
a)NameMichael Bolinder
2Reason for the notification
a)Position/status Chief Executive Officer/PDMR
b)Initial notification/ Amendment Initial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameAcacia Pharma Group plc 
b)LEI213800SLDKXWKT6E3381
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument

 

Identification code 
Ordinary Shares of £0.02 each

 

 

 

GB00BYWF9Y76
b)Nature of the transactionAllotment of Ordinary Shares following vesting of share award under
the Company's Performance Share Plan
c)Price(s) and volume(s)75,000 Ordinary Shares at a price of £0.02 pence per share
d)Aggregated information
- Aggregated volume
- Price

 
N/A
e)Date of the transaction12 October 2020

 
f)Place of the transactionEuronext Brussels (XBRU)

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com  

 
International Media
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com
US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com
Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be